In the current context of China's rapidly growing economy, multinational drug companies are investing significantly in research and development in China, a trend that has accelerated over the last 10 years. A robust regulatory framework, an abundance of highly equipped medical universities and large patient numbers in all therapy areas make China an increasingly attractive location to conduct clinical research. In addition, data from China are now accepted for inclusion in applications for market authorisation by regulatory agencies worldwide, including the Food and Drug Administration (FDA) in the US. Hence China is becoming an equal partner in global clinical development, a trend that is likely to grow significantly in the years to come.
展开▼
